home / stock / cwbr / cwbr news

CWBR News and Press, CohBar Inc. From 05/06/20

Stock Information
Company Name: CohBar Inc.
Stock Symbol: CWBR
Market: OTC
Website: cohbar.com
Menu
CWBR CWBR Quote CWBR Short CWBR News CWBR Articles CWBR Message Board
Get CWBR Alerts

News, Short Squeeze, Breakout and More Instantly...
CWBR - CohBar Looks Undervalued Ahead Of Upcoming Data Readout

CohBar ( CWBR ) is a company working to combat the diseases of aging that has tremendous upside potential. This is because the markets they are targeting-NASH, obesity, type 2 diabetes, fibrotic diseases, and cancer-are all huge, yet the company's market cap is under $150 million. CohBar is se...
CWBR - CohBar To Target COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with its Apelin Receptor Agonist Peptides

MENLO PARK, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that it has initiated testing of its CB5064 analogs in p...

CWBR - CohBar's Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced its poster abstract for the  American Thoracic Society (A...

CWBR - CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020

MENLO PARK, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2...
CWBR - CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference

MENLO PARK, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced acceptance of a late-breaking abstract as a poster pre...

CWBR - CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

MENLO PARK, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it is anticipating delays in the completion of it...

CWBR - CohBar, Inc. 2019 Q4 - Results - Earnings Call Presentation

The following slide deck was published by CohBar, Inc. in conjunction with their 2019 Q4 earnings Read more ...

CWBR - CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript

CohBar, Inc. (CWBR) Q4 2019 Earnings Conference Call March 12, 2020 5:00 PM ET Company Participants Jordyn Tarazi – Director-Investor Relations Jeff Biunno – Chief Financial Officer Steve Engle – Chief Executive Officer Ken Cundy – Chief Scientific O...

CWBR - CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today reported its financial results for the fourth quarter end...

CWBR - CohBar to Hold Investor Meetings at the ROTH Virtual Conference

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will hold its planned investor meetin...
Previous 10 Next 10